Eli Lilly says its diabetes drug tirzepatide gets approval in China-March 2024-www.financetom.com

Eli Lilly says its diabetes drug tirzepatide gets approval in China

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Eli Lilly says its diabetes drug tirzepatide gets approval in China

May 21, 2024 12:17 AM

SHANGHAI, May 21 (Reuters) - Eli Lilly ( LLY ) said on

Tuesday its tirzepatide drug has received approval from Chinese

regulators for use to treat type 2 diabetes.

Tirzepatide is the active ingredient in the U.S. firm's

diabetes drug Mounjaro and weight-loss drug Zepbound.

(Reporting by Andrew Silver; Editing by Muralikumar

Anantharaman)

Previous page： Alto Neuroscience Says Phase 2b Study in Major Depressive Disorder Fails to Meet Primary Endpoint Next page： --Mueller Water Products Increases Quarterly Dividend to $0.067 per Share From $0.064; Payable Nov. 20 to Shareholders of Record on Nov. 8

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Alto Neuroscience Says Phase 2b Study in Major Depressive Disorder Fails to Meet Primary Endpoint

Oct 23, 2024

04:06 AM EDT, 10/23/2024 (MT Newswires) -- Alto Neuroscience ( ANRO ) said late Tuesday a phase 2b study of ALTO-100 in patients with major depressive disorder failed to meet its primary endpoint compared with placebo. Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker, Alto Neuroscience ( ANRO...

--Mueller Water Products Increases Quarterly Dividend to $0.067 per Share From $0.064; Payable Nov. 20 to Shareholders of Record on Nov. 8

Oct 23, 2024

04:03 AM EDT, 10/23/2024 (MT Newswires) -- Price: 22.01, Change: -0.06, Percent Change: -0.27 ...

High Roller Technologies Prices IPO at $8 per Share

Oct 23, 2024

04:13 AM EDT, 10/23/2024 (MT Newswires) -- High Roller Technologies ( ROLR ) , an online gaming operator, said late Tuesday it priced its initial public offering of 1.25 million shares at $8 per share for gross proceeds of $10 million. The company has also granted the underwriters a 45-day option to purchase up to an additional 187,500 shares to...

FrontView REIT Says IPO Underwriters Exercised Option to Buy Additional Shares

Oct 23, 2024

04:02 AM EDT, 10/23/2024 (MT Newswires) -- FrontView REIT ( FVR ) said Tuesday that the underwriters of its initial public offering have exercised their option to buy an additional of about 1.1 million common shares at the IPO price of $19 per share, less underwriting discounts and commissions. The option closing is expected to settle Wednesday. The company said...